UniQuest is one of Australia’s largest commercialisation companies and the first choice for investors in early-stage technologies.

We have a solid track record, based on 25+ years’ experience, including 60 plus start-up companies which have raised more than $250 million collectively, with several successfully establishing international markets for their products.

UniQuest has licensed more than 250 products to industry, and global product sales have exceeded $5.2 billion. These licences include the basis for the world’s first cervical cancer vaccine, Gardasil; a magnetic resonance imaging (MRI) technology contained in more than 70 per cent of the world’s high-field MRI; and the Triple P positive parenting program, which is available in 20 languages and 18 countries.

Our team will work with you to select and package suitable technologies. The intellectual assets within our portfolio have strategies in place to optimise their value and market potential.

Disclaimer:
UniQuest’s website content is for information purposes only and does not constitute nor is it intended to constitute financial product advice. You must conduct your own due diligence before making an investment. Please read our full disclaimer.